Abbott Labs Files Q1 2025 10-Q
Ticker: ABT · Form: 10-Q · Filed: 2025-04-30T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, quarterly-report, financials
TL;DR
Abbott Labs dropped its Q1 2025 10-Q. Check financials.
AI Summary
Abbott Laboratories filed its 10-Q for the period ending March 31, 2025. The filing details the company's financial performance and position, including its fiscal year end of December 31st. Specific financial figures and operational details for the first quarter of 2025 are presented.
Why It Matters
This filing provides investors and analysts with the latest financial data for Abbott Laboratories, crucial for understanding the company's current health and future prospects.
Risk Assessment
Risk Level: low — This is a routine quarterly filing providing standard financial disclosures.
Key Numbers
- 2025-03-31 — Period End Date (Quarterly reporting period)
- 2025-01-01 — Period Start Date (Quarterly reporting period)
- 2024-03-31 — Prior Year Quarter End (Comparison period)
Key Players & Entities
- ABBOTT LABORATORIES (company) — Filer
- 0001628280-25-021090 (filing_id) — Accession Number
- 20250331 (date) — Period of Report
- 20250430 (date) — Filed as of Date
- 100 ABBOTT PARK ROAD (address) — Business Address
- IL (state) — State of Incorporation
- 1231 (date) — Fiscal Year End
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is March 31, 2025.
When was this 10-Q filing submitted?
This 10-Q filing was submitted on April 30, 2025.
What is Abbott Laboratories' fiscal year end?
Abbott Laboratories' fiscal year ends on December 31st.
What is the company's primary business address?
The company's primary business address is 100 Abbott Park Road, Abbott Park, IL 60064-3500.
What is the SIC code for Abbott Laboratories?
The Standard Industrial Classification (SIC) code for Abbott Laboratories is 2834, Pharmaceutical Preparations.
From the Filing
0001628280-25-021090.txt : 20250430 0001628280-25-021090.hdr.sgml : 20250430 20250430161432 ACCESSION NUMBER: 0001628280-25-021090 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 78 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250430 DATE AS OF CHANGE: 20250430 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABBOTT LABORATORIES CENTRAL INDEX KEY: 0000001800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 360698440 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-02189 FILM NUMBER: 25895383 BUSINESS ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 BUSINESS PHONE: 2246676100 MAIL ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 10-Q 1 abt-20250331.htm 10-Q abt-20250331 0000001800 12-31 2025 Q1 false false false false false P12M http://fasb.org/us-gaap/2024#LongTermDebtNoncurrent http://fasb.org/us-gaap/2024#LongTermDebtNoncurrent xbrli:shares iso4217:USD iso4217:USD xbrli:shares abt:segment xbrli:pure 0000001800 2025-01-01 2025-03-31 0000001800 exch:XCHI 2025-01-01 2025-03-31 0000001800 exch:XNYS 2025-01-01 2025-03-31 0000001800 2025-03-31 0000001800 2024-01-01 2024-03-31 0000001800 2024-12-31 0000001800 us-gaap:CommonStockMember 2024-12-31 0000001800 us-gaap:CommonStockMember 2023-12-31 0000001800 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000001800 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000001800 us-gaap:CommonStockMember 2025-03-31 0000001800 us-gaap:CommonStockMember 2024-03-31 0000001800 us-gaap:TreasuryStockCommonMember 2024-12-31 0000001800 us-gaap:TreasuryStockCommonMember 2023-12-31 0000001800 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0000001800 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0000001800 us-gaap:TreasuryStockCommonMember 2025-03-31 0000001800 us-gaap:TreasuryStockCommonMember 2024-03-31 0000001800 us-gaap:RetainedEarningsMember 2024-12-31 0000001800 us-gaap:RetainedEarningsMember 2023-12-31 0000001800 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000001800 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000001800 us-gaap:RetainedEarningsMember 2025-03-31 0000001800 us-gaap:RetainedEarningsMember 2024-03-31 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000001800 us-gaap:NoncontrollingInterestMember 2024-12-31 0000001800 us-gaap:NoncontrollingInterestMember 2023-12-31 0000001800 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-03-31 0000001800 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0000001800 us-gaap:NoncontrollingInterestMember 2025-03-31 0000001800 us-gaap:NoncontrollingInterestMember 2024-03-31 0000001800 2023-12-31 0000001800 2024-03-31 0000001800 country:US us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2025-01-01 2025-03-31 0000001800 us-gaap:NonUsMember us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2025-01-01 2025-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2025-01-01 2025-03-31 0000001800 country:US us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2024-01-01 2024-03-31 0000001800 us-gaap:NonUsMember us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsM